Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
19
pubmed:dateCreated
2008-10-2
pubmed:abstractText
A novel series of symmetrical ureas of [(7-amino(2-naphthyl))sulfonyl]phenylamines were designed, synthesized, and tested for their ability to increase glucose transport in mouse 3T3-L1 adipocytes, a surrogate readout for activation of the insulin receptor (IR) tyrosine kinase (IRTK). A structure-activity relationship was established that indicated glucose transport activity was dependent on the presence of two acidic functionalities, two sulfonamide linkages, and a central urea or 2-imidazolidinone core. Compound 30 was identified as a potent and selective IRTK activator. At low concentrations, 30 was able to increase the tyrosine phosphorylation of the IR stimulated by submaximal insulin. At higher concentrations, 30 was able to increase tyrosine the phosphorylation levels of the IR in the absence of insulin. When administered intraperitoneally (ip) and orally (po), 30 improved glucose tolerance in hypoinsulinemic, streptozotocin-treated rats. These data provide pharmacological validation that small molecule IRTK activators represent a potential new class of antidiabetic agents.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1520-4804
pubmed:author
pubmed:issnType
Electronic
pubmed:day
9
pubmed:volume
51
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6173-87
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:18788731-3T3-L1 Cells, pubmed-meshheading:18788731-Adipocytes, pubmed-meshheading:18788731-Administration, Oral, pubmed-meshheading:18788731-Aniline Compounds, pubmed-meshheading:18788731-Animals, pubmed-meshheading:18788731-Binding Sites, pubmed-meshheading:18788731-Blood Glucose, pubmed-meshheading:18788731-Cells, Cultured, pubmed-meshheading:18788731-Dose-Response Relationship, Drug, pubmed-meshheading:18788731-Drug Design, pubmed-meshheading:18788731-Drug Evaluation, Preclinical, pubmed-meshheading:18788731-Fibroblasts, pubmed-meshheading:18788731-Glucose Tolerance Test, pubmed-meshheading:18788731-Injections, Intraperitoneal, pubmed-meshheading:18788731-Male, pubmed-meshheading:18788731-Mice, pubmed-meshheading:18788731-Molecular Structure, pubmed-meshheading:18788731-Phosphorylation, pubmed-meshheading:18788731-Rats, pubmed-meshheading:18788731-Rats, Sprague-Dawley, pubmed-meshheading:18788731-Receptor, Insulin, pubmed-meshheading:18788731-Stereoisomerism, pubmed-meshheading:18788731-Streptozocin, pubmed-meshheading:18788731-Structure-Activity Relationship, pubmed-meshheading:18788731-Sulfonamides, pubmed-meshheading:18788731-Urea
pubmed:year
2008
pubmed:articleTitle
Design, synthesis, and structure-activity relationships of novel insulin receptor tyrosine kinase activators.
pubmed:affiliation
Telik, Inc., 3165 Porter Drive, Palo Alto, California 94304, USA.
pubmed:publicationType
Journal Article